Apellis Pharmaceuticals Inc Foglalás / Részvény
Mi az Apellis Pharmaceuticals Inc Foglalás / Részvény?
A Foglalás / Részvény az Apellis Pharmaceuticals Inc - 1.37
Mi a Foglalás / Részvény meghatározása?
Az egy részvényre jutó könyv szerinti érték egy vállalat eszköze, mínusz kötelezettségek, osztva a fennálló részvények számával.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Foglalás / Részvény a Health Care szektor a NASDAQ-on cégekben a Apellis Pharmaceuticals Inc -hoz képest
Mit csinál Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
foglalás / részvény -hoz hasonló cégek Apellis Pharmaceuticals Inc
- Hopening SA nak Foglalás / Részvény 1.37 van
- Sunniva nak Foglalás / Részvény 1.37 van
- Imdex nak Foglalás / Részvény 1.37 van
- CYBERDYNE nak Foglalás / Részvény 1.37 van
- Agfa-Gevaert NV nak Foglalás / Részvény 1.37 van
- Europa Oil & Gas () Plc nak Foglalás / Részvény 1.37 van
- Apellis Pharmaceuticals Inc nak Foglalás / Részvény 1.37 van
- Blue Sky Alternative Investments nak Foglalás / Részvény 1.37 van
- Micropole SA nak Foglalás / Részvény 1.37 van
- Destiny Pharma plc nak Foglalás / Részvény 1.37 van
- Hot Chili nak Foglalás / Részvény 1.38 van
- The Barkby PLC nak Foglalás / Részvény 1.38 van
- Cuisine Solutions nak Foglalás / Részvény 1.38 van